Our laboratory studies and develops adoptive T cell therapies targeting solid tumors.
The scientist will develop genetically engineered T cells starting from the molecular cloning phase of cell therapy development, and then advancing to preclinical in vitro work and clinically relevant mouse models.
An additional focus will be to develop strategies to recruit neoantigen-targeted immunity.
A strong background in molecular biology and immunology will allow the successful applicant to be creative within the lab, enhancing T cell function and tumor targeting for optimal patient translation and high impact publication.
The scientist will work under the mentorship of lead faculty within the Center for Immunotherapy (CFI), which holds multiple large level grants and houses a highly collaborative group of investigators – including immunologists, molecular biologists, and computational biologists – dedicated to developing immune therapies.